K. Jessen

发表

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

S. Burley, A. Corbin, M. Deininger, 2006 .

Retinol binding protein expression is induced in HepG2 cells by zinc deficiency

C. Keen, K. Jessen, M. Clegg, 2001, FEBS letters.

Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity

Shunyou Wang, Katrina Chan, C. Rommel, 2009 .

Selective inhibition of MET protein receptor tyrosine kinase by SGX523

J. M. Sauder, S. Burley, J. Blaney, 2007 .

In vitro and in vivo antitumor activities of SGX523, a novel MET inhibitor

S. Burley, Marshall C. Peterman, K. Froning, 2007 .

A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid.

D. Green, L. Qiu, S. Kasibhatla, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Cyclic AMP regulation of mouse proline-rich protein gene expression: isoproterenol induction of AP-1 transcription factors in parotid glands.

D. M. Carlson, P. Wright, E. Wong, 1997, Archives of biochemistry and biophysics.

Induction of mouse retinol binding protein gene expression by cyclic AMP in Hepa 1-6 cells.

K. Jessen, M. Satre, 1998, Archives of biochemistry and biophysics.

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib

Stephen K Burley, Sean Buchanan, Kevin Holme, 2008, Proceedings of the National Academy of Sciences.

Mouse retinol binding protein gene: Cloning, expression and regulation by retinoic acid

K. Jessen, M. Satre, 2000, Molecular and Cellular Biochemistry.

Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin

J. Gregg, R. Cardiff, L. Young, 2004, Breast Cancer Research.

The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach

L. Qiu, S. Kasibhatla, S. Cai, 2005, Molecular Cancer Therapeutics.

A phase I, first-in-human, dose escalation study of intravenous TK216 in patients with relapsed or refractory Ewing sarcoma.

J. Ludwig, J. Toretsky, N. Daw, 2017 .